Qiagen N.V.

ots Ad hoc-Service: Qiagen N.V. QIAGEN Genomics signs agreements with . Daiichi Pure Chemicals, Co Ltd. . University of Washington

Mitteilung gemäß Paragraph 15 WpHG, übermittelt von der DGAP Für den Inhalt ist allein der Emittent verantwortlich -----------------------------------------------------

    Venlo,NL (ots Ad hoc-Service) -      Karen Hedine General Manager
QIAGEN Genomics, Inc. (425)398-3140

    email: k.hedine@qiagengenomics.com

    Peer M. Schatz Chief Financial Officer QIAGEN N.V. 011-49-2103-2911-702

    email: p.schatz@de.QIAGEN.com

    Noonan/Russo Communications, Inc. Mary Claire Bice (212)696-4455

    QIAGEN Genomics signs agreements with . Daiichi Pure Chemicals, Co Ltd. . University of Washington

    QIAGEN Genomics, Inc., a wholly-owned subsidiary of QIAGEN N.V. (NASDAQ: QGENF, Frankfurt/Neuer Markt: QIA, EASDAQ: QGEN) today announced two agreements.

    Agreement No. 1: QIAGEN Genomics enters technology access agreement with Daiichi Pure Chemicals, Co. LTD., Japan QIAGEN Genomics, Inc., today announced that it has entered into a technology access and purchase agreement with Daiichi Pure Chemicals, Co. Ltd., (DPC) a wholly owned subsidiary of Daiichi Pharmaceutical Co. Ltd., Japan.

    Under the terms of the non-exclusive agreement, QIAGEN Genomics will sell its MasscodeTM systems for high throughput single nucleotide polymorphism (SNP) genotyping to DPC. QIAGEN Genomics' technologies will enable DPC to provide SNP genotyping services. The agreement requires that DPC purchase its SNP genotyping chemistry and instrumentation from QIAGEN Genomics for a five-year period. QIAGEN Genomics will provide DPC with training and support during DPC's initial year of providing SNP genotyping services to researchers in Japan. Financial terms were not disclosed.

    DPC is a leading provider of services on behalf of clients in Japan. With QIAGEN Genomics' MasscodeTM system, the company intends to offer SNP genotyping in addition to its range of toxicology and diagnostic services. The market for genomic in Japan is expanding rapidly with the government financing an estimated $40 million to join the race for mapping of the human genome and identification of disease- drug associations based on SNPs.

    The QIAGEN Genomics' MasscodeTM system permits simultaneous analysis of 15 SNPs per well from a 96-well plate format, making it the only deeply multiplexable genotyping technology available today. This is a consequence of a unique mass-spectrometry based detection system which capitalizes on novel, photocleavable, allele-specific, oligonucleotides tagged with low molecular weight markers and dedicated software that has been developed by the company for digital conversion of massive amounts of mass spectral data. Assays are highly quantitative and precise, and require minimal amounts of genomic DNA.

    Agreement No. 2: QIAGEN GENOMICS ENTERS SNP GENOTYPING RESEARCH AGREEMENT WITH UNIVERSITY OF WASHINGTON QIAGEN Genomics, Inc., today announced further that it has entered into a research and license agreement with the University of Washington's (UW) School of Pharmacy regarding QIAGEN Genomics' MasscodeTM technology for high throughput single nucleotide polymorphism (SNP) genotyping of cytochrome P450 (CYP) enzymes.

    To facilitate the UW's current CYP SNP genotyping program objectives and future extension into other pharmacogenetic determinants of drug disposition, such as drug transporter polymorphisms, the UW School of Pharmacy has acquired a limited, non-exclusive right to use QIAGEN Genomics' MasscodeTM high throughput SNP genotyping technology for certain, specifically defined, projects.

    As part of its agreement with UW, QIAGEN Genomics obtains the exclusive right to negotiate with UW for an exclusive worldwide license with respect to any new invention, development, biological material or discovery in genotyping that results from UW's use of MasscodeTM system in its CYP program.

    CYP enzymes metabolize an enormous array of therapeutic agents, and the UW's School of Pharmacy is widely recognized for its research into the role that the cytochrome P450 enzymes play in metabolism-based drug interactions and other drug toxicities. CYP SNPs are major determinants of inter- individual variability in drug response, occasionally causing serious adverse drug reactions in patients who have genetically-determined defective forms of these enzymes.

    Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with the challenges of integrating newly-acquired businesses into QIAGEN's operations, management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing and genomics market, nucleic acid- based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's products (including seasonal fluctuations), difficulties in successfully adapting the Company's products to integrated solutions and producing such products, the Company's ability to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that the Company has filed with the U.S. Securities and Exchange Commission (SEC).

    End of Message

----------------------------------------------------- Internet: http://recherche.newsaktuell.de

Original-Content von: Qiagen N.V., übermittelt durch news aktuell

Weitere Meldungen: Qiagen N.V.

Das könnte Sie auch interessieren: